Financials · KRYS

Krystal Biotech Inc. (KRYS) financials

For the twelve months ended Sep 30, 2026, Krystal Biotech Inc. reported $470.02M of revenue and $225.17M of net income.

Revenue, TTM
$470.02M
Revenue growth, YoY
+26.0%
Net income, TTM
$225.17M
Net income growth, YoY
+13.2%
Net margin
47.9%
Free cash flow, TTM
$310.08M
EPS, diluted, TTM
$7.36
EPS growth, YoY
+10.2%
Cash
$462.84M
P/E
39.21
P/S
18.78
Market cap
$8.83B
Annual revenue$389.13M
FY2021FY2025
Annual net income$204.83M
FY2016FY2025
Annual free cash flow$188.91M
FY2016FY2025

KRYS revenue and earnings growth

KRYS revenueQ3 2026$127.34M

Quarter YoY
+30.2%
QoQ
+6.8%
FY YoY
+33.9%

KRYS revenue was $127.34M in fiscal Q3 2026 (ended Sep 30, 2026), up 30.2% from a year earlier and up 6.8% from the prior quarter. For the full fiscal 2025 it was $389.13M, up 33.9% from fiscal 2024. Fiscal 2025 is the highest of the 5 fiscal years on file.

KRYS net incomeQ3 2026$63.07M

Quarter YoY
-20.5%
QoQ
+15.2%
FY YoY
+129.7%

KRYS net income was $63.07M in fiscal Q3 2026 (ended Sep 30, 2026), down 20.5% from a year earlier and up 15.2% from the prior quarter. For the full fiscal 2025 it was $204.83M, up 129.7% from fiscal 2024. Fiscal 2025 is the highest of the 10 fiscal years on file.

KRYS EPSQ3 2026$2.05

Quarter YoY
-22.9%
QoQ
+14.5%
FY YoY
+128.0%

KRYS diluted EPS was $2.05 in fiscal Q3 2026 (ended Sep 30, 2026), down 22.9% from a year earlier and up 14.5% from the prior quarter. For the full fiscal 2025 it was $6.84, up 128.0% from fiscal 2024.

KRYS free cash flowQ3 2026$90.25M

Quarter YoY
+137.8%
QoQ
+26.7%
FY YoY
+58.5%

KRYS free cash flow was $90.25M in fiscal Q3 2026 (ended Sep 30, 2026), up 137.8% from a year earlier and up 26.7% from the prior quarter. For the full fiscal 2025 it was $188.91M, up 58.5% from fiscal 2024. Fiscal 2025 is the highest of the 10 fiscal years on file.

Export CSV

Income statement

Income statement
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Revenue$389.13M$290.51M$50.70M$0$0-----
Research and development$58.05M$53.58M$46.43M$42.46M$27.88M$17.94M$15.62M$7.76M$3.21M$741.0K
Selling, general and admin$146.74M$113.63M$98.29M$77.73M$40.39M$15.06M$6.46M$4.16M$1.56M$402.0K
Operating income$161.29M$65.75M-$109.62M-$145.20M-$68.28M-$33.00M-$22.08M-$11.92M-$4.77M-$1.14M
Interest expense--$0$0$1.49M$0----
Pre-tax income$189.47M$95.36M$12.90M-$139.97M-$69.57M-----
Income tax-$15.36M$6.20M$1.97M$0$0$0$0$0$0-
Net income$204.83M$89.16M$10.93M-$139.97M-$69.57M-$32.17M-$19.09M-$10.89M-$7.92M-$1.15M
EPS, basic$7.08$3.12$0.40-$5.49-$3.13-$1.71-$1.20-$0.97-$1.48-$1.31
EPS, diluted$6.84$3.00$0.39-$5.49-$3.13-$1.71-$1.20-$0.97-$1.48-$1.31
Diluted shares30.0M29.7M27.8M25.5M22.2M18.8M15.9M11.2M5.4M877,490

Balance sheet

Balance sheet
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Cash and equivalents$496.30M$344.87M$358.33M$161.90M$341.25M$268.27M$187.51M$103.67M$49.59M$1.92M
Receivables$127.42M$104.75M$42.04M$0------
Inventory$40.48M$26.51M$6.99M$0------
Current assets$1.02B$742.04M$587.91M$383.78M$442.27M$275.06M$195.88M$112.65M$49.91M$2.17M
Total assets$1.33B$1.06B$818.36M$558.45M$626.29M$310.84M$209.02M$116.12M$50.11M$2.18M
Current liabilities$102.94M$102.00M$33.09M$28.85M$25.74M$15.45M$3.33M$2.60M$640.0K$43.0K
Long-term debt---------$1.15M
Total debt---------$1.15M
Total liabilities$114.23M$109.46M$39.71M$36.22M$32.72M$18.76M$6.11M$2.89M$640.0K$1.89M
Shareholders' equity$1.22B$946.38M$778.64M$522.23M$593.58M$292.08M$202.91M$113.23M$49.47M$289.0K

Cash flow

Cash flow
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Operating cash flow$200.87M$123.42M-$88.80M-$100.57M-$47.94M-$26.08M-$18.69M-$9.45M-$3.89M-$1.31M
Capital expenditures$11.95M$4.24M$11.80M$52.98M$68.34M$14.84M$6.40M$2.23M$210.0K$15.0K
Free cash flow$188.91M$119.18M-$100.60M-$153.55M-$116.27M-$40.93M-$25.09M-$11.68M-$4.10M-$1.33M
Investing cash flow-$58.42M-$163.44M$82.64M-$114.08M-$226.77M-$11.18M-$4.99M-$10.32M-$210.0K-$15.0K
Financing cash flow$8.71M$27.01M$202.75M$35.35M$347.69M$118.02M$107.53M$73.85M$51.77M$3.25M
Stock-based compensation$54.51M$49.13M$39.93M$33.23M$15.32M$3.27M$1.24M$792.0K$246.0K$33.0K
Depreciation and amortization---$4.05M$2.77M$1.85M$1.09M---

Key ratios

Key ratios
Line item
Dec 31, 2025
Dec 31, 2024
Dec 31, 2023
Dec 31, 2022
Dec 31, 2021
Dec 31, 2020
Dec 31, 2019
Dec 31, 2018
Dec 31, 2017
Dec 31, 2016
Revenue growth, YoY33.9%473.0%--------
Net income growth, YoY129.7%715.6%--------
EPS growth, YoY128.0%669.2%--------
Operating margin41.5%22.6%-216.2%-------
Net margin52.6%30.7%21.6%-------
Free cash flow margin48.5%41.0%-198.4%-------
Return on equity16.8%9.4%1.4%-26.8%-11.7%-11.0%-9.4%-9.6%-16.0%-397.9%
Return on assets15.4%8.4%1.3%-25.1%-11.1%-10.3%-9.1%-9.4%-15.8%-52.7%
Current ratio9.957.2817.7613.3017.1817.8058.8843.3977.9950.44
Debt to equity---------3.96

Source: XBRL data Krystal Biotech Inc. files with the SEC, latest filing dated Nov 2, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.

* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.

Per-share figures are as filed. The filings show no stock split in these periods.

EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.

KRYS peers

CompanyRevenueGrowthNet incomeNet marginMarket cap
KRYS$470.02M+26.0%$225.17M47.9%$8.83B
LEGN$1.03B+64.0%-$296.80M-28.8%$3.11B
EDSA---$14.10M-$25.5M
MBRX$0--$11.42M-$7.6M

KRYS FAQ

8 questions
  • What is KRYS revenue?
    Krystal Biotech Inc. (KRYS) reported $470.02M of revenue for the twelve months ended Sep 30, 2026. That is up 26.0% from the year before. Revenue for fiscal 2025 was $389.13M.
  • Is KRYS profitable?
    Yes. Krystal Biotech Inc. earned $225.17M in net income for the twelve months ended Sep 30, 2026, a net margin of 47.9%.
  • How much cash and debt does KRYS have?
    Krystal Biotech Inc. reported $462.84M in cash and cash equivalents on its most recent balance sheet in SEC filings.
  • How fast is KRYS revenue growing?
    Krystal Biotech Inc.'s revenue changed +33.9% in fiscal 2025, to $389.13M.
  • What is KRYS free cash flow?
    Krystal Biotech Inc. generated $310.08M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of $323.93M less capital expenditures.
  • What is KRYS earnings per share?
    Diluted earnings per share were $7.36 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.
  • When did KRYS last report financial results?
    The latest statements here come from Krystal Biotech Inc.'s 10-Q filed on Nov 2, 2026, covering the period ended Sep 30, 2026.
  • Where does this KRYS financial data come from?
    Quantisnow builds these statements from the structured XBRL data Krystal Biotech Inc. files with the SEC. It is provided for information only and is not investment advice.